Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein
Open Access
- 14 February 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 68 (5) , 1040-1053
Abstract
Fenofibrate, a peroxisome proliferator–activated receptor α (PPARα) agonist, reduces lower limb amputations in patients with type 2 diabetes. The mechanism is, however, unknown. In this study, we demonstrate that fenofibrate markedly attenuates diabetes-related impairment of ischemia-mediated angiogenesis. In a murine model of hindlimb ischemia, daily oral fenofibrate treatment restored diabetes-impaired blood flow recovery, foot movement, hindlimb capillary density, vessel diameter, and vascular endothelial growth factor signaling to nondiabetic levels in both wild-type and PPARα-knockout mice, indicating that these fenofibrate effects are largely PPARα independent. In vitro, fenofibric acid (FFA) rescued high glucose–induced (25 mmol/L) impairment of endothelial cell migration, tubulogenesis, and survival in a PPARα-independent manner. Interestingly, fenofibrate in vivo and FFA in vitro reversed high glucose–induced expression of thioredoxin-interacting protein (TXNIP), an exquisitely glucose-inducible gene previously identified as a critical mediator of diabetes-related impairment in neovascularization. Conversely, adenoviral overexpression of TXNIP abrogated the restorative effects of FFA on high glucose–impaired endothelial cell function in vitro, indicating that the effects of FFA are mediated by TXNIP. We conclude that fenofibrate rescues diabetic impairment in ischemia-mediated angiogenesis, in large part, by PPARα-independent regulation of TXNIP. These findings may therefore explain the reduction in amputations seen in patients with diabetes treated with fenofibrate.Keywords
Funding Information
- National Health and Medical Research Council of Australia (512299, 1066541)
This publication has 37 references indexed in Scilit:
- A Ligand-Independent VEGFR2 Signaling Pathway Limits Angiogenic Responses in DiabetesScience Signaling, 2014
- Medical strategies to reduce amputation in patients with Type 2 diabetesDiabetic Medicine, 2013
- The Emerging Role of the Thioredoxin System in AngiogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trialThe Lancet, 2009
- Risks of Nontraumatic Lower-Extremity Amputations in Patients with Type 1 DiabetesDiabetes Care, 2008
- New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying HypothesisImmunology, Endocrine & Metabolic Agents in Medicinal Chemistry, 2007
- The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Cardiovascular Diabetology, 2004
- Update on FenofibrateCardiovascular Drug Reviews, 2002
- Effect of Diabetes Mellitus on Formation of Coronary Collateral VesselsCirculation, 1999
- Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGFThe American Journal of Pathology, 1999